All News
Filter News
Found 2,542 articles
-
Broad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus Variants, Says NanoViricides, Inc.’s President, Dr. Anil Diwan
1/27/2021
NanoViricides, Inc. a global leader in the development of highly effective broad-spectrum antiviral therapies based on a novel nanomedicines platform, discusses the current developments in the COVID-19 pandemic and the Company's exciting accomplishments related to it.
-
TrialScope Supports Moderna for Diversity Enrollment in Moderna’s Phase 3 Study of its COVID-19 Vaccine
1/27/2021
Fulfilling a commitment to diversity and inclusion in the Phase 3 COVE Study of the Moderna COVID-19 Vaccine, Moderna enlisted the help of TrialScope, the global leader in clinical trial disclosure and transparency technology, for patient recruitment. Moderna utilized TrialScope Connect, an industry-first patient
-
Lonza Reports Strong 2020 Performance, Driven By Sales Growth in Pharma and Biotech Business
1/27/2021
“The full-year results reflect our commitment and focus to maintaining operations throughout the COVID-19 pandemic, while making an active and decisive contribution to controlling it.
-
Moderna Confirms Discussions with U.S. Government for Additional 100 Million Doses of the Moderna COVID-19 Vaccine
1/27/2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today confirmed that the Company is in discussion with the U.S. government to purchase an additional 100 million doses of the Moderna COVID-19 Vaccine for delivery in the third quarter of 2021.
-
British scientists suggested last week that the U.K. variant may be approximately 30% more lethal than the most common strain that came out of China. But they’re not completely sure of this yet.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 26, 2021.
-
Moderna Provides U.S. COVID-19 Vaccine Supply Update
1/26/2021
Jan. 26, 2021 13:04 UTC Company has supplied over 30 million doses to U.S. Government to date Remains on track to deliver 100 million doses to the U.S. Government by end of March 2021 Remains on track to deliver 200 million doses to the U.S. Government by end of June 2021 CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today provided a supply update for the
-
NORD and Partners Host FDA, CDC Leaders in Webinar Addressing Rare Disease Community on COVID-19 Vaccines
1/26/2021
In an effort to provide clear, useful, authoritative information to rare disease patients and caregivers on the COVID-19 vaccines, on January 15 the National Organization for Rare Disorders, along with The ALS Association, Cystic Fibrosis Foundation and Muscular Dystrophy Association, hosted a special webinar with leaders from the US Food and Drug Administration and the Centers for Disease Control and Prevention.
-
Merck announced that it is going to stop developing its two COVID-19 vaccine candidates, dubbed V590 and V591, after poor responses in Phase I trials.
-
Moderna announced it has started development on a booster to its COVID-19 vaccine, which the company hopes will work against the recently discovered (and more transmissible) SARS-CoV-2 variant from South Africa.
-
Pfizer, Moderna, AstraZeneca, and Johnson & Johnson all have trials of their respective vaccines underway in various age-groups.
-
Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa
1/25/2021
Out of an abundance of caution, Moderna launches clinical program to boost immunity to emerging variants Manuscript posted to preprint server; company to host conference call once manuscript is available
-
Moderna to Host Conference Call on COVID-19 Variants Announcement on Monday, Jan. 25
1/25/2021
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will hold a conference call today, Monday, January 25 at 4:30 pm ET on the Company’s announcement that results from in vitro neutralization studies of sera from individuals vaccinated with Moderna COVID-19 Vaccine showing activity against emerging strains of SARS-CoV-2.
-
CPHO Issue Statement Series on COVID-19: Keeping Up COVID-19 Public Health Measures
1/24/2021
Over the last month, the authorization of two COVID-19 vaccines offered many Canadians – myself included – hope that the end of the pandemic is in sight.
-
One year and more than 410,000 deaths later, the United States is still firmly in the grips of the COVID-19 pandemic.
-
With the Pfizer-BioNTech and Moderna COVID-19 vaccines currently authorized in the U.S. and being distributed and dosed, some of the attention is shifting to Johnson & Johnson’s efforts for its one-shot vaccine.
-
Americans are still hesitant to be vaccinated against COVID-19, according to just-released research from Invisibly.
-
The decision was made based on an Independent Data Monitoring Committee recommendation which indicated the study was unlikely to meet its specified primary efficacy endpoint of progression-free survival.
-
Moderna Announces First Participant Dosed in Phase 1/2 Study of Moderna COVID-19 Vaccine in Japan Led by Takeda
1/21/2021
Moderna Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in the Phase 1/2 study of Moderna’s vaccine candidate against COVID-19 (mRNA-1273 or TAK-919) in Japan, led by Takeda Pharmaceutical Co., Ltd (NYSE: TAK). TAK-919 is Takeda’s development code for Moderna’s COVID-19 vaccine candidate.
-
Aviva Pharmacy Provides Initial Doses of COVID-19 Vaccine
1/21/2021
Aviva Pharmacy, an independent pharmacy located in Long Beach, CA has announced that it has obtained supplies of both the Moderna and Pfizer COVID-19 vaccines and has begun administering vaccinations to health care providers and those 65 years of age or older in Long Beach.